SAN terminates Genasense deal with Genta

GNTA announced after market close that sanofi-aventis (Euronext:SAN; SNY) terminated the companies' deal to develop GNTA's Genasense oblimersen antisense compound for cancer.

Read the full 227 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE